Hereditary Angioedema Treatment Market Size and Growth Rate:

“The Global Hereditary Angioedema Treatment Market is expected to reach US$ 7,010.2 Mn by 2025 owing to growth in R&D for the development of newer drugs”.

Hereditary Angioedema Treatment Market Growth Drivers and Restraints:

The global hereditary angioedema treatment market is expected to reach US$ 7,010.2 Mn by 2025. The major factors streaming the growth of global hereditary angioedema treatment market is rise in prevalence of hereditary angioedema. Government is also taking initiatives to increase the research and development activities in the field of hereditary angioedema. Moreover, majority of the players are also investing in the research and development activities to find out the cure and make novel drugs due to the increasing prevalence of the disease. Furthermore, lifestyle changes and more improved healthcare infrastructure are also aiding in the growth of hereditary angioedema treatment market. On the flip side, about 25% of those affected die in the first two decades of life, mainly due to lack of treatment or because of higher cost of prophylaxis. Moreover, the type-III hereditary angioedema pathology is unknown hence treatment is not available. These factors block the growth of global hereditary angioedema treatment market.

Browse More Details of the report @ https://www.precisionbusinessinsights.com/market-reports/global-hereditary-angioedema-treatment-market/

C1 Esterase Inhibitors Dominate the Global Hereditary Angioedema Treatment Market

Based on the drug class, global hereditary angioedema treatment market is segmented into C1 esterase inhibitors, plasma kallikrein inhibitors (ecallantide), bradykinin receptor antagonists (icatibant), corticosteroids, antihistamines, autoimmune drugs, blood protein controllers, and antifibrinolytic agents. C1 esterase inhibitors tend to dominate the global hereditary angioedema treatment market owing to more research activities going on the C1 esterase inhibitors, more demand of these drugs in the market, and it is the major cause of type-I hereditary angioedema.

North America Leads the Global Hereditary Angioedema Treatment Market

PBI’s global hereditary angioedema treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America dominated the global hereditary angioedema treatment market through 2014-2018 and expected to dominate over 2019-2025 due rising prevalence of hereditary angioedema in the region, well established healthcare system, and more availability of treatment options. Their ongoing research and development actives for novel therapeutics are also aiding in their hereditary angioedema treatment market growth. After North America, Europe dominates the global hereditary angioedema treatment market due their rising demand for preventive medical care, advanced diagnosis, and high healthcare expenditure. Middle East, Asia, and Africa hereditary angioedema treatment market will grow at a low pace due to high cost of drugs, improper diagnosis, and limited availability of treatment options in some of the countries.
Launch of newer drug products, and strategic alliances are the key strategies adopted by market players

Global hereditary angioedema treatment market further reveals that the key player’s increasingly adopting strategies such as launch of newer drug products, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance,
 In June 2017, CSL Behring got approval from US FDA for its therapeutic product HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) to treat hereditary angioedema.
 In August 2018, Shire got US FDA’s approval for “TAKHZYRO” as a preventive treatment for hereditary angioedema.

Key player’s profiles in the report are CSL Limited (Australia), Shire (Republic of Ireland), BioCryst Pharmaceuticals, Inc. (U.S), Salix Pharmaceuticals (U.S), and Pharming Group NV (Netherlands).

Ask For Sample of the report @ https://www.precisionbusinessinsights.com/request-sample?product_id=15707

Detailed Segmentation of Hereditary Angioedema Treatment Market:

By Type
• Type-I
• Type-II
• Type-III

By Drug Class
• C1 esterase inhibitors
• Plasma kallikrein inhibitors (Ecallantide)
• Bradykinin receptor antagonists (Icatibant)
• Corticosteroids
• Antihistamines
• Autoimmune drugs
• Blood protein controllers
• Antifibrinolytic agents

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others

Geography

o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.

Contact Us:

Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights